Medical Oncologist
Lung Cancer and Rare Thoracic Tumours
Lung cancer is one of the most common malignancies, but recent advances have substantially changed how it is managed. At the same time, the management of rare thoracic tumours, such as mesothelioma and thymoma, requires specific clinical expertise. Treatment decisions are now guided by molecular profiling of the tumour (biomarker testing), allowing contemporary options such as immunotherapy and targeted therapies to be used, with the aim of achieving meaningful disease control and maintaining quality of life.
Specialist Assessment and Management
As each tumour has its own distinct biological characteristics, the treatment strategy should be carefully individualised.
Non-Small-Cell Lung Cancer (NSCLC)
This is the most common type of lung cancer. Today, treatment decisions are based primarily on molecular testing (the tumour’s genetic profile). Depending on the specific findings, treatment may include immunotherapy or targeted therapies. The appropriate integration of these treatments into clinical practice has led to meaningful improvements in prognosis and survival.
Small-Cell Lung Cancer (SCLC)
This form of lung cancer is characterised by rapid progression, making prompt diagnosis and timely initiation of treatment essential. Current treatment is generally based on a combination of chemotherapy and immunotherapy, with the aim of achieving more effective disease control.
Malignant Pleural Mesothelioma
A rare tumour arising in the pleura, the membrane surrounding the lungs, and often associated with asbestos exposure. Whereas treatment was traditionally based on a limited number of chemotherapy agents, immunotherapy has now substantially changed the treatment pathway and expanded the options available to patients.
Thymoma and Thymic Carcinoma
These are rare tumours arising in the thymus, within the anterior mediastinum. Their clinical behaviour varies considerably—from the generally slower course of thymomas to the more aggressive behaviour of thymic carcinomas—and their management therefore requires careful staging.
Solitary Fibrous Tumour (SFT)
This is a rare mesenchymal tumour, often identified incidentally on imaging performed for an unrelated reason. Its clinical behaviour can range from indolent to more aggressive. Surgical resection remains the preferred treatment where feasible. In more complex or advanced disease, treatment is individualised, and long-term follow-up is required because late recurrence may occur.